< Back to previous page
Researcher
Bart Keymeulen
- Research Expertise:
Full professor of Medicine - Vrije Universiteit Brussel
Head Diabetes Clinic & Clinical Trial Center - UZ Brussel
Head Research Cluster Diabetes - Vrije Universiteit Brussel
Head Diabetes Biobank associated with Belgian Diabetes Registry
- Keywords:Medicine
- Disciplines:Endocrinology and metabolic diseases not elsewhere classified, Immunology not elsewhere classified
- Users of research expertise:
Full professor of Medicine - Vrije Universiteit Brussel
Head Diabetes Clinic & Clinical Trial Center - UZ Brussel
Head Research Cluster Diabetes - Vrije Universiteit Brussel
Head Diabetes Biobank associated with Belgian Diabetes Registry
Affiliations
- Diabetes Pathology & Therapy (Research group)
Responsible
From2 Feb 2011 → Today - Diabetes Clinic (Department)
Member
From1 Jan 2008 → Today - Clinical sciences (Department)
Member
From1 Oct 2023 → Today - Pathology/molecular and cellular medicine (Department)
Member
From1 Oct 2019 → 30 Apr 2024 - Pathology/molecular and cellular medicine (Department)
Member
From8 Apr 2019 → 30 Sep 2023 - Pathology/molecular and cellular medicine (Department)
Responsible
From1 Jan 2014 → 20 Oct 2022 - Pathology/molecular and cellular medicine (Department)
Member
From1 Jan 2014 → 30 Sep 2016 - Internal Medicine Specializations (Department)
Member
From1 Apr 1997 → 31 Dec 2013 - Pathologic Biochemistry and Physiology (Department)
Member
From1 Oct 1989 → 31 Dec 2013
Projects
1 - 10 of 11
- Plasma proinsulin and proinsulin/C-peptide ratio to facilitate prediction for progression to type 1 diabetes in at risk individualsFrom1 Nov 2024 → TodayFunding: FWO fellowships
- Biologic Platform for Early Detection, Prevention and Treatment of Type 1 DiabetesFrom1 Mar 2024 → TodayFunding: BOF - projects
- Hilde Bruers prijs 2022From12 May 2022 → 11 May 2024Funding: Universities as sponsor
- Predicting impending beta cell loss and dysglycemia in asymptomatic type 1 diabetes - Validation of minimally invasive markers against the hyperglycemic clamp test.From1 Nov 2021 → 30 Sep 2025Funding: FWO fellowships
- SRP-Onderzoekszwaartepunt: Platform for Clinical Trial Network to Prevent and Cure Type 1 DiabetesFrom1 Mar 2019 → 29 Feb 2024Funding: BOF - projects
- Beta Cell Generation by Stem Cell-Derived Implants in DiabetesFrom1 Dec 2015 → 31 Aug 2022Funding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- SRP (Groeiers): Biomarkers for staging diabetes and guiding its prevention and treatmentFrom1 Mar 2014 → 28 Feb 2019Funding: BOF - Concerted Research Project from 1994
- Innovation in diagnosis, prevention and treatment of type 1 diabetes.From1 Nov 2013 → 31 Oct 2019Funding: FWO Applied Biomedical Research (TBM)
- Therapeutic potential of composing human beta cell implant in the treatment of diabetes.From1 Mar 2010 → 28 Feb 2014Funding: FWO Applied Biomedical Research (TBM)
- BetaCellTherapy : Beta Cell Therapy in Diabetes.From1 Jan 2010 → 30 Jun 2015Funding: Health
Publications
1 - 10 of 137
- One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes(2025)Published in: DiabetologiaISSN: 0012-186XIssue: 5Volume: 68Pages: 948-960
- The stage- and subgroup-specific impact of non-HLA polymorphisms on preclinical type 1 diabetes progression(2025)Published in: HeliyonISSN: 2405-8440Issue: 3Volume: 11
- Continuous glucose monitor metrics from five studies identify participants at risk for type 1 diabetes development(2025)Published in: DiabetologiaISSN: 0012-186XVolume: 68Pages: 930-939
- Biomarkers of beta cell loss, dysglycemia and responsiveness to immune intervention in (a)symptomatic type 1 diabetes(2025)Number of pages: 237
- 74-OR: ADA Presidents' Select Abstract: CGM Metrics from Five Studies Identify Participants at High Risk of Imminent Type 1 Diabetes (T1D) Development(2024)Published in: DiabetesISSN: 0012-1797Volume: 73
- Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium(2024)Published in: DiabetologiaISSN: 0012-186XIssue: 4Volume: 67Pages: 650-662
- Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes(2024)Published in: Nat BiotechnolISSN: 1087-0156Issue: 10Volume: 42Pages: 1507-1514
- The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes(2024)Published in: Journal of diabetes science and technologyISSN: 1932-2968Issue: 3Volume: 18Pages: 660-666
- Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes(2023)Published in: N. Engl. J. Med.ISSN: 0028-4793Issue: 23Volume: 389Pages: 2151-2161
- Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes(2023)Published in: Diabetes Res Clin PractISSN: 0168-8227Volume: 205